bluuebunny/crossref_metadata_2025 huggingface dataset:
A Compact Horizontal Coaxial to Ridge Gap Waveguide Transition for Ka-Band
Authors: Tao Changjian , Zheng Haidong , Jin Chuan
Published: September 2023

This paper presents a novel type of compact inline coaxial to ridge gap waveguide (RGW) transition, which covers the whole Ka frequency band. The structure connects with the connector's inner conductor through a rectangular probe directly. The probe is set in nail bed without any extra parts. Hence, a simple and compact transition comes to fruition at the circuit topology level. This transition can be considered as an inhomogeneous stripline, so the characteristic impedance can be analyzed similarly to the stripline. Beyond this, a mounting hole is drilled at rectangular probe to improve the robustness and convenience of assembly without welding or conductive adhesive bonding. To verify the performance of the proposed structure, a back-to-back transition is designed, fabricated, and measured. Measurement results achieve better than 20 dB return loss and about 0.15 dB insertion loss from 26.4 GHz to 40.4 GHz. It corresponds greatly with simulation results and bespeaks valuable in millimeter-wave applications.
Role of Voltage Control Devices in Low Voltage State Estimation Process
Authors: Táczi István , Vokony István , Barancsuk Lilla , Péter Gábor Mihály , Tőzsér Balázs , Hartmann Bálint
Published: September 2023

Megatrends, such as the proliferation of distributed generation, electrification, and the appearance of aggregator companies, put the low voltage power grids under intense pressure. Since the network infrastructure developments cannot keep up with the trends, distribution system operators turned to alternative solutions. Smart grid assets, such as on-load tap-changing distribution transformers or serial low voltage regulators, are promising solutions. However, the energy transition cannot be handled with the network expansive on the distribution level. Control centers are predicted to expand to this voltage level in the near future, and distribution system state estimation could be an enabler of all functionalities. On the low voltage level, data scarcity is a great challenge in observability; therefore, research must focus on the creation of pseudomeasurements and integration of available data sources. This paper examines the inclusion of smart assets from the conceptual point to the application on two sites, based on data from operational environments, both with a pseudomeasurement and an integrated metering point approach. The results showed that integrating smart assets could considerably mitigate voltage fluctuations, and reduce estimation errors by two magnitudes on the low voltage network.
Nursing 12-Hour Shifts and Patient Incidents in Mental Health and Community Hospitals: A Longitudinal Study Using Routinely Collected Data
Authors: Dall’Ora Chiara , Ejebu Ourega-Zoé , Jones Jeremy , Griffiths Peter
Published: September 2023

Shifts of 12 hours or longer are common in nursing services within general hospital wards. Concerns have been raised about their safety, but previous research has mostly used staff-reported measures of quality and safety and has occurred in general hospital settings only. This study aims to measure the association between the use of 12+ hour shifts in nursing staff (including registered nurses, healthcare support workers or nursing assistants, and nursing associates) and the rate of patient incidents in mental health and community hospitals. This is a longitudinal study using routinely collected data from two mental health and community NHS trusts in the South of England. We accessed rosters of nursing staff and patient incident data from April 2018 to March 2021. We extracted 1,018,971 shifts and excluded those not worked by nursing staff, with a final sample of 898,143 shifts. We extracted 53,078 incidents. We only included incidents that involved patients and that occurred in wards. Our final sample consisted of 38,373 patient incidents. We linked all patient incidents and nurses’ worked shifts at the ward-day level. Depending on the distribution of incident rates, we used either negative binomial mixed-effects models or Poisson mixed-effect models to investigate the association between the proportion of 12+ hour shifts and all patient incidents, violence against staff, falls, self-injury, disruptive behaviour, and medication management incidents at the ward-day level. We found a relationship between 12+ hour shifts and the incident rate. Compared to days in wards with no long shifts, increasing the proportion of long shifts was initially associated with a small increase in the overall rate of incidents, but the rate increased sharply as the proportion of long shifts was above 70%. Rates of self-injury increased more steadily as the proportion of long shifts increased. The mandatory implementation of long shifts should be discouraged.
Hamiltonian Neural Network 6-DoF Rigid-Body Dynamic Modeling Based on Energy Variation Estimation
Authors: Simiao Fei , Lin Huo , Zhixiao Sun , He Wang , Yuanjie Lu , Jile He , Qing Luo , Qihang Su
Published: September 2023

This study introduces a novel deep modeling approach that utilizes Hamiltonian neural networks to address the challenges of modeling the six degrees of freedom rigid-body dynamics induced by control inputs in various domains such as aerospace, robotics, and automotive engineering. The proposed method is based on the principles of Hamiltonian dynamics and employs an inductive bias in the form of a constructed bias for both conservative and varying energies, effectively tackling the modeling issues arising from time-varying energy in controlled rigid-body dynamics. This constructed bias captures the information regarding the changes in the rigid body’s energy. The presented method not only achieves highly accurate modeling but also preserves the inherent bidirectional time-sliding inference in Hamiltonian-based modeling approaches. Experimental results demonstrate that our method outperforms existing techniques in the time-varying six degrees of freedom dynamic modeling of aircraft and missile guidance, enabling high-precision modeling and feedback correction. The findings of our research hold significant potential for the kinematic modeling of time-varying energy systems, parallel system state prediction and control, inverse motion inference, and autonomous decision-making in military applications.
Supplementary Data from Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody–Drug Conjugate for the Treatment of Cancer
Authors: Toader Dorin , Fessler Shawn P. , Collins Scott D. , Conlon Patrick R. , Bollu Reddy , Catcott Kalli C. , Chin Chen-Ni , Dirksen Anouk , Du Bingfan , Duvall Jeremy R. , Higgins Stacy , Kozytska Mariya V. , Bellovoda Kamela , Faircloth Chelsey , Lee David , Li Fu , Qin Liuliang , Routhier Caitlin , Shaw Pamela , Stevenson Cheri A. , Wang Jason , Wongthida Phonphimon , Ter-Ovanesyan Elena , Ditty Elizabeth , Bradley Stephen P. , Xu Ling , Yin Mao , Yurkovetskiy Alexandr V. , Mosher Rebecca , Damelin Marc , Lowinger Timothy B.
Published: September 2023

Supplementary Materials
Figure S5 from S-531011, a Novel Anti-Human CCR8 Antibody, Induces Potent Antitumor Responses through Depletion of Tumor-Infiltrating CCR8-Expressing Regulatory T Cells
Authors: Nagira Yoji , Nagira Morio , Nagai Ryohei , Nogami Wataru , Hirata Michinari , Ueyama Azumi , Yoshida Tetsuya , Yoshikawa Mai , Shinonome Satomi , Yoshida Hiroshi , Haruna Miya , Miwa Hiroto , Chatani Natsumi , Ohkura Naganari , Wada Hisashi , Tanaka Hidekazu
Published: September 2023

In vivo anti-tumor activity of S-531011 in CT26.WT or EMT6 tumor-bearing mice model.
Figure S4 from S-531011, a Novel Anti-Human CCR8 Antibody, Induces Potent Antitumor Responses through Depletion of Tumor-Infiltrating CCR8-Expressing Regulatory T Cells
Authors: Nagira Yoji , Nagira Morio , Nagai Ryohei , Nogami Wataru , Hirata Michinari , Ueyama Azumi , Yoshida Tetsuya , Yoshikawa Mai , Shinonome Satomi , Yoshida Hiroshi , Haruna Miya , Miwa Hiroto , Chatani Natsumi , Ohkura Naganari , Wada Hisashi , Tanaka Hidekazu
Published: September 2023

Binding profile of the newly created CCR8 antibody
Supplementary Figure 8 from AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors
Authors: Weng Weining , Meng Tao , Pu Junyi , Ma Linjie , Shen Yi , Wang Zhaohui , Pan Rong , Wang Mingqiao , Chen Caiwei , Wang Lijun , Zhang Jianjian , Zhou Biao , Shao Siyuan , Qian Yu , Liu Shuhui , Hu Wenhao , Meng Xun
Published: September 2023

In vitro efficacy and bystander effect of AMT-562.
Supplementary Figure 7 from AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors
Authors: Weng Weining , Meng Tao , Pu Junyi , Ma Linjie , Shen Yi , Wang Zhaohui , Pan Rong , Wang Mingqiao , Chen Caiwei , Wang Lijun , Zhang Jianjian , Zhou Biao , Shao Siyuan , Qian Yu , Liu Shuhui , Hu Wenhao , Meng Xun
Published: September 2023

Orthogonal combination experiments of HER3 targeting ADCs and trafficking parameters of AMT-562.
Supplementary Figure 6 from AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors
Authors: Weng Weining , Meng Tao , Pu Junyi , Ma Linjie , Shen Yi , Wang Zhaohui , Pan Rong , Wang Mingqiao , Chen Caiwei , Wang Lijun , Zhang Jianjian , Zhou Biao , Shao Siyuan , Qian Yu , Liu Shuhui , Hu Wenhao , Meng Xun
Published: September 2023

Pharmacokinetics of HER3-targeting ADCs.
Table S2 from T Cell–intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic Leukemia
Authors: Lam Vi , Roleder Carly , Liu Tingting , Bruss Nur , Best Scott , Wang Xiaoguang , Phillips Tycel , Shouse Geoffrey , Berger Allison J. , Alinari Lapo , Wang Lili , Siddiqi Tanya , Pennock Nathan D. , Danilov Alexey V.
Published: September 2023

Table S2 shows fluorochrome-conjugated anti-mouse antibodies used for flow cytometry experiments
Table S1 from T Cell–intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic Leukemia
Authors: Lam Vi , Roleder Carly , Liu Tingting , Bruss Nur , Best Scott , Wang Xiaoguang , Phillips Tycel , Shouse Geoffrey , Berger Allison J. , Alinari Lapo , Wang Lili , Siddiqi Tanya , Pennock Nathan D. , Danilov Alexey V.
Published: September 2023

Table S1 shows fluorochrome-conjugated anti-human antibodies used for flow cytometry or FACS experiments
Supplementary Data Methods from T Cell–intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic Leukemia
Authors: Lam Vi , Roleder Carly , Liu Tingting , Bruss Nur , Best Scott , Wang Xiaoguang , Phillips Tycel , Shouse Geoffrey , Berger Allison J. , Alinari Lapo , Wang Lili , Siddiqi Tanya , Pennock Nathan D. , Danilov Alexey V.
Published: September 2023

Supplementary methods
Supplementary Figure 2 from AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors
Authors: Weng Weining , Meng Tao , Pu Junyi , Ma Linjie , Shen Yi , Wang Zhaohui , Pan Rong , Wang Mingqiao , Chen Caiwei , Wang Lijun , Zhang Jianjian , Zhou Biao , Shao Siyuan , Qian Yu , Liu Shuhui , Hu Wenhao , Meng Xun
Published: September 2023

HER3 expression level and hydrophilicity of Ab562 ADCs.
Figure S1, Figure S2, Figure S3, Figure S4, Figure S5, Figure S6, Table S1 from Upregulation of Somatostatin Receptor Type 2 Improves 177Lu-DOTATATE Therapy in Receptor-Deficient Pancreatic Neuroendocrine Tumor Model
Authors: Sharma Rupali , Earla Bhargav , Baidoo Kwamena E. , Zeiger Martha A. , Madigan James P. , Escorcia Freddy E. , Sadowski Samira M.
Published: September 2023

Supplementary Figures and Tables with Legend
Supplementary Figure 1 from AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors
Authors: Weng Weining , Meng Tao , Pu Junyi , Ma Linjie , Shen Yi , Wang Zhaohui , Pan Rong , Wang Mingqiao , Chen Caiwei , Wang Lijun , Zhang Jianjian , Zhou Biao , Shao Siyuan , Qian Yu , Liu Shuhui , Hu Wenhao , Meng Xun
Published: September 2023

Generation and characterization of Ab562, a novel HER3-targeting antibody.
Supplementary Figures from Targeting Upregulated cIAP2 in SOX10-Deficient Drug Tolerant Melanoma
Authors: Glasheen McKenna Q. , Caksa Signe , Young Amelia G. , Wilski Nicole A. , Ott Connor A. , Chervoneva Inna , Flaherty Keith T. , Herlyn Meenhard , Xu Xiaowei , Aplin Andrew E. , Capparelli Claudia
Published: September 2023

Supplementary Figures 1-4
Supplementary Data from Targeting Upregulated cIAP2 in SOX10-Deficient Drug Tolerant Melanoma
Authors: Glasheen McKenna Q. , Caksa Signe , Young Amelia G. , Wilski Nicole A. , Ott Connor A. , Chervoneva Inna , Flaherty Keith T. , Herlyn Meenhard , Xu Xiaowei , Aplin Andrew E. , Capparelli Claudia
Published: September 2023

Full size western blots
Table S8 from Pan-Cancer Pharmacogenomic Analysis of Patient-Derived Tumor Cells Using Clinically Relevant Drug Exposures
Authors: Chang Stephen H. , Ice Ryan J. , Chen Michelle , Sidorov Maxim , Woo Rinette W.L. , Rodriguez-Brotons Aida , Jian Damon , Kim Han Kyul , Kim Angela , Stone David E. , Nazarian Ari , Oh Alyssia , Tranah Gregory J. , Nosrati Mehdi , de Semir David , Dar Altaf A. , Desprez Pierre-Yves , Kashani-Sabet Mohammed , Soroceanu Liliana , McAllister Sean D.
Published: September 2023

Supplementary Table 8 FGFR mutations
Supplementary table 1 from FOXN Transcription Factors: Regulation and Significant Role in Cancer
Authors: Song Jiali , Li Longshan , Fang Yang , Lin Yue , Wu Luojia , Wan Wei , Wei Gen , Hua Fuzhou , Ying Jun
Published: September 2023

Supplementary table 1
Table S5 from Pan-Cancer Pharmacogenomic Analysis of Patient-Derived Tumor Cells Using Clinically Relevant Drug Exposures
Authors: Chang Stephen H. , Ice Ryan J. , Chen Michelle , Sidorov Maxim , Woo Rinette W.L. , Rodriguez-Brotons Aida , Jian Damon , Kim Han Kyul , Kim Angela , Stone David E. , Nazarian Ari , Oh Alyssia , Tranah Gregory J. , Nosrati Mehdi , de Semir David , Dar Altaf A. , Desprez Pierre-Yves , Kashani-Sabet Mohammed , Soroceanu Liliana , McAllister Sean D.
Published: September 2023

Supplementary Table 5 LOBICO data
Supplementary Figure 1, 2 and Table 1,2 from FOXN Transcription Factors: Regulation and Significant Role in Cancer
Authors: Song Jiali , Li Longshan , Fang Yang , Lin Yue , Wu Luojia , Wan Wei , Wei Gen , Hua Fuzhou , Ying Jun
Published: September 2023

Supplementary Figure 1, 2 and Table 1,2
Supplementary Figure 1 from FOXN Transcription Factors: Regulation and Significant Role in Cancer
Authors: Song Jiali , Li Longshan , Fang Yang , Lin Yue , Wu Luojia , Wan Wei , Wei Gen , Hua Fuzhou , Ying Jun
Published: September 2023

Supplementary Figure 1
Table S2 from Pan-Cancer Pharmacogenomic Analysis of Patient-Derived Tumor Cells Using Clinically Relevant Drug Exposures
Authors: Chang Stephen H. , Ice Ryan J. , Chen Michelle , Sidorov Maxim , Woo Rinette W.L. , Rodriguez-Brotons Aida , Jian Damon , Kim Han Kyul , Kim Angela , Stone David E. , Nazarian Ari , Oh Alyssia , Tranah Gregory J. , Nosrati Mehdi , de Semir David , Dar Altaf A. , Desprez Pierre-Yves , Kashani-Sabet Mohammed , Soroceanu Liliana , McAllister Sean D.
Published: September 2023

Supplementary Table 2 pancancer clinical info
Table S1 from Pan-Cancer Pharmacogenomic Analysis of Patient-Derived Tumor Cells Using Clinically Relevant Drug Exposures
Authors: Chang Stephen H. , Ice Ryan J. , Chen Michelle , Sidorov Maxim , Woo Rinette W.L. , Rodriguez-Brotons Aida , Jian Damon , Kim Han Kyul , Kim Angela , Stone David E. , Nazarian Ari , Oh Alyssia , Tranah Gregory J. , Nosrati Mehdi , de Semir David , Dar Altaf A. , Desprez Pierre-Yves , Kashani-Sabet Mohammed , Soroceanu Liliana , McAllister Sean D.
Published: September 2023

Supplementary Table 1 drug concentrations
Data from Upregulation of Somatostatin Receptor Type 2 Improves 177Lu-DOTATATE Therapy in Receptor-Deficient Pancreatic Neuroendocrine Tumor Model
Authors: Sharma Rupali , Earla Bhargav , Baidoo Kwamena E. , Zeiger Martha A. , Madigan James P. , Escorcia Freddy E. , Sadowski Samira M.
Published: September 2023

Abstract
Pancreatic neuroendocrine tumors (PNET) express high levels of somatostatin receptor type 2 (SSTR2), a unique target for both tumor imaging and therapy. This surface expression is lost in metastatic high-grade PNETs, making patients ineligible for SSTR2-targeted 177 Lutetium (Lu)-DOTATATE peptide receptor radionuclide therapy (PRRT), and represents an unmet clinical need. Here, we aimed to restore SSTR2 expression through the reversal of inhibitory epigenetic gene silencing to improve tumor responsiveness to PRRT. We first assessed human SSTR2 promoter methylation and expression levels in 96 patient samples. We then used three NET cell lines (QGP-1, BON-1, GOT-1) with variable SSTR2 expression profiles for functional in vitro studies using histone deacetylase inhibitors (HDACi). Finally, the QGP-1 xenograft mouse model, with low basal SSTR2 expression, was used to assess the therapeutic efficacy of combined HDACi and 177Lu-DOTATATE therapies. We confirm that SSTR expression is decreased and correlates with SSTR2 promoter methylation in patients with high-grade NETs. When exposed to HDACis, SSTR2 surface expression is increased in three NET cell lines in vitro. In an in vivo PNET xenograft model with low basal SSTR2 expression, our studies demonstrate significantly higher tumor uptake of SSTR2-targeted 177Lu-DOTATATE in animals pretreated with HDACis compared with controls. For the first time, we show that this higher tumor uptake results in significant antitumor response when compared with standard PRRT alone. These preclinical results provide a rationale for utilizing HDACi pretreatment to improve targeted radionuclide therapy in patients with SSTR2-negative, metastatic PNETs.
Supplementary Video S9 from Dynamic Glycoprotein Hyposialylation Promotes Chemotherapy Evasion and Metastatic Seeding of Quiescent Circulating Tumor Cell Clusters in Breast Cancer
Authors: Dashzeveg Nurmaa K. , Jia Yuzhi , Zhang Youbin , Gerratana Lorenzo , Patel Priyam , Shajahan Asif , Dandar Tsogbadrakh , Ramos Erika K. , Almubarak Hannah F. , Adorno-Cruz Valery , Taftaf Rokana , Schuster Emma J. , Scholten David , Sokolowski Michael T. , Reduzzi Carolina , El-Shennawy Lamiaa , Hoffmann Andrew D. , Manai Maroua , Zhang Qiang , D'Amico Paolo , Azadi Parastoo , Colley Karen J. , Platanias Leonidas C. , Shah Ami N. , Gradishar William J. , Cristofanilli Massimo , Muller William A. , Cobb Brian A. , Liu Huiping
Published: September 2023

Supplementary Video S9 shows the clustering video of siALCAM1 transfected ST6KO cells presented in Fig.5E.
Supplementary Video S8 from Dynamic Glycoprotein Hyposialylation Promotes Chemotherapy Evasion and Metastatic Seeding of Quiescent Circulating Tumor Cell Clusters in Breast Cancer
Authors: Dashzeveg Nurmaa K. , Jia Yuzhi , Zhang Youbin , Gerratana Lorenzo , Patel Priyam , Shajahan Asif , Dandar Tsogbadrakh , Ramos Erika K. , Almubarak Hannah F. , Adorno-Cruz Valery , Taftaf Rokana , Schuster Emma J. , Scholten David , Sokolowski Michael T. , Reduzzi Carolina , El-Shennawy Lamiaa , Hoffmann Andrew D. , Manai Maroua , Zhang Qiang , D'Amico Paolo , Azadi Parastoo , Colley Karen J. , Platanias Leonidas C. , Shah Ami N. , Gradishar William J. , Cristofanilli Massimo , Muller William A. , Cobb Brian A. , Liu Huiping
Published: September 2023

Supplementary Video S8 shows the clustering video of scrRNA transfected ST6KO cells presented in Fig.5E.
Supplementary Video S7 from Dynamic Glycoprotein Hyposialylation Promotes Chemotherapy Evasion and Metastatic Seeding of Quiescent Circulating Tumor Cell Clusters in Breast Cancer
Authors: Dashzeveg Nurmaa K. , Jia Yuzhi , Zhang Youbin , Gerratana Lorenzo , Patel Priyam , Shajahan Asif , Dandar Tsogbadrakh , Ramos Erika K. , Almubarak Hannah F. , Adorno-Cruz Valery , Taftaf Rokana , Schuster Emma J. , Scholten David , Sokolowski Michael T. , Reduzzi Carolina , El-Shennawy Lamiaa , Hoffmann Andrew D. , Manai Maroua , Zhang Qiang , D'Amico Paolo , Azadi Parastoo , Colley Karen J. , Platanias Leonidas C. , Shah Ami N. , Gradishar William J. , Cristofanilli Massimo , Muller William A. , Cobb Brian A. , Liu Huiping
Published: September 2023

Supplementary Video S7 shows the clustering video of PBS treated cells presented in Fig.2E
Supplementary Data Tables from A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development
Authors: Dickinson Michael J. , Barba Pere , Jäger Ulrich , Shah Nirav N. , Blaise Didier , Briones Javier , Shune Leyla , Boissel Nicolas , Bondanza Attilio , Mariconti Luisa , Marchal Anne-Laure , Quinn David S. , Yang Jennifer , Price Andrew , Sohoni Akash , Treanor Louise M. , Orlando Elena J. , Mataraza Jennifer , Davis Jaclyn , Lu Darlene , Zhu Xu , Engels Boris , Moutouh-de Parseval Laure , Brogdon Jennifer L. , Moschetta Michele , Flinn Ian W.
Published: September 2023

Supplementary Table S1. Bridging chemotherapies by ATC class and preferred term (safety set); Supplementary Table S2. Lymphodepleting chemotherapies (safety set); Supplementary Table S3. Cytokine release syndrome following YTB323 infusion; Supplementary Table S4. Neurological adverse reactions following YTB323 infusion; Supplementary Table S5. Summary of cellular kinetic parameters in peripheral blood by flow cytometry for YTB323 at DL1 and DL2; Supplementary Table S6. Summary of cellular kinetic parameters in peripheral blood by flow cytometry and qPCR for YTB323 at DL1 and DL2.
Supplementary Video S2 from Dynamic Glycoprotein Hyposialylation Promotes Chemotherapy Evasion and Metastatic Seeding of Quiescent Circulating Tumor Cell Clusters in Breast Cancer
Authors: Dashzeveg Nurmaa K. , Jia Yuzhi , Zhang Youbin , Gerratana Lorenzo , Patel Priyam , Shajahan Asif , Dandar Tsogbadrakh , Ramos Erika K. , Almubarak Hannah F. , Adorno-Cruz Valery , Taftaf Rokana , Schuster Emma J. , Scholten David , Sokolowski Michael T. , Reduzzi Carolina , El-Shennawy Lamiaa , Hoffmann Andrew D. , Manai Maroua , Zhang Qiang , D'Amico Paolo , Azadi Parastoo , Colley Karen J. , Platanias Leonidas C. , Shah Ami N. , Gradishar William J. , Cristofanilli Massimo , Muller William A. , Cobb Brian A. , Liu Huiping
Published: September 2023

Supplementary Video S2 shows the clustering video of SNA low cells presented in Fig.2A.
Supplementary Table 9 from A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy
Authors: Pei Shanshan , Shelton Ian T. , Gillen Austin E. , Stevens Brett M. , Gasparetto Maura , Wang Yanan , Liu Lina , Liu Jun , Brunetti Tonya M. , Engel Krysta , Staggs Sarah , Showers William , Sheth Anagha Inguva , Amaya Maria L. , Minhajuddin Mohammad , Winters Amanda , Patel Sweta B. , Tolison Hunter , Krug Anna E. , Young Tracy N. , Schowinsky Jeffrey , McMahon Christine M. , Smith Clayton A. , Pollyea Daniel A. , Jordan Craig T.
Published: September 2023

PDX experiments
Supplementary Table 8 from A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy
Authors: Pei Shanshan , Shelton Ian T. , Gillen Austin E. , Stevens Brett M. , Gasparetto Maura , Wang Yanan , Liu Lina , Liu Jun , Brunetti Tonya M. , Engel Krysta , Staggs Sarah , Showers William , Sheth Anagha Inguva , Amaya Maria L. , Minhajuddin Mohammad , Winters Amanda , Patel Sweta B. , Tolison Hunter , Krug Anna E. , Young Tracy N. , Schowinsky Jeffrey , McMahon Christine M. , Smith Clayton A. , Pollyea Daniel A. , Jordan Craig T.
Published: September 2023

Metabolomic analysis of m-LSC versus non m-LSC
Supplementary Video S16 from Dynamic Glycoprotein Hyposialylation Promotes Chemotherapy Evasion and Metastatic Seeding of Quiescent Circulating Tumor Cell Clusters in Breast Cancer
Authors: Dashzeveg Nurmaa K. , Jia Yuzhi , Zhang Youbin , Gerratana Lorenzo , Patel Priyam , Shajahan Asif , Dandar Tsogbadrakh , Ramos Erika K. , Almubarak Hannah F. , Adorno-Cruz Valery , Taftaf Rokana , Schuster Emma J. , Scholten David , Sokolowski Michael T. , Reduzzi Carolina , El-Shennawy Lamiaa , Hoffmann Andrew D. , Manai Maroua , Zhang Qiang , D'Amico Paolo , Azadi Parastoo , Colley Karen J. , Platanias Leonidas C. , Shah Ami N. , Gradishar William J. , Cristofanilli Massimo , Muller William A. , Cobb Brian A. , Liu Huiping
Published: September 2023

Supplementary Video S16 shows the clustering video of siALCAM1 transfected ST6WT cells presented in Supplementary Fig.S14B.
Supplementary Table 6 from A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy
Authors: Pei Shanshan , Shelton Ian T. , Gillen Austin E. , Stevens Brett M. , Gasparetto Maura , Wang Yanan , Liu Lina , Liu Jun , Brunetti Tonya M. , Engel Krysta , Staggs Sarah , Showers William , Sheth Anagha Inguva , Amaya Maria L. , Minhajuddin Mohammad , Winters Amanda , Patel Sweta B. , Tolison Hunter , Krug Anna E. , Young Tracy N. , Schowinsky Jeffrey , McMahon Christine M. , Smith Clayton A. , Pollyea Daniel A. , Jordan Craig T.
Published: September 2023

List of specimens used for CITE-seq analysis
Supplementary Table 1 from A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy
Authors: Pei Shanshan , Shelton Ian T. , Gillen Austin E. , Stevens Brett M. , Gasparetto Maura , Wang Yanan , Liu Lina , Liu Jun , Brunetti Tonya M. , Engel Krysta , Staggs Sarah , Showers William , Sheth Anagha Inguva , Amaya Maria L. , Minhajuddin Mohammad , Winters Amanda , Patel Sweta B. , Tolison Hunter , Krug Anna E. , Young Tracy N. , Schowinsky Jeffrey , McMahon Christine M. , Smith Clayton A. , Pollyea Daniel A. , Jordan Craig T.
Published: September 2023

Clinical information of primary AML specimens
Supplementary Video S14 from Dynamic Glycoprotein Hyposialylation Promotes Chemotherapy Evasion and Metastatic Seeding of Quiescent Circulating Tumor Cell Clusters in Breast Cancer
Authors: Dashzeveg Nurmaa K. , Jia Yuzhi , Zhang Youbin , Gerratana Lorenzo , Patel Priyam , Shajahan Asif , Dandar Tsogbadrakh , Ramos Erika K. , Almubarak Hannah F. , Adorno-Cruz Valery , Taftaf Rokana , Schuster Emma J. , Scholten David , Sokolowski Michael T. , Reduzzi Carolina , El-Shennawy Lamiaa , Hoffmann Andrew D. , Manai Maroua , Zhang Qiang , D'Amico Paolo , Azadi Parastoo , Colley Karen J. , Platanias Leonidas C. , Shah Ami N. , Gradishar William J. , Cristofanilli Massimo , Muller William A. , Cobb Brian A. , Liu Huiping
Published: September 2023

Supplementary Video S14 shows the clustering video of scrRNA transfected ST6WT cells presented in Fig.5E.
Supplementary Figures S1-S7 from A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy
Authors: Pei Shanshan , Shelton Ian T. , Gillen Austin E. , Stevens Brett M. , Gasparetto Maura , Wang Yanan , Liu Lina , Liu Jun , Brunetti Tonya M. , Engel Krysta , Staggs Sarah , Showers William , Sheth Anagha Inguva , Amaya Maria L. , Minhajuddin Mohammad , Winters Amanda , Patel Sweta B. , Tolison Hunter , Krug Anna E. , Young Tracy N. , Schowinsky Jeffrey , McMahon Christine M. , Smith Clayton A. , Pollyea Daniel A. , Jordan Craig T.
Published: September 2023

Supplementary Fig. 1: Immunophenotyping and WES analysis of primary AML specimens. Supplementary Fig. 2: Immunophenotyping of engrafted cells in PDX. Supplementary Fig. 3: WES analysis and remission duration of VEN/AZA relapsed AML patients. Supplementary Fig. 4: CITE-seq data analysis. Supplementary Fig. 5: Sorting strategies for determining m-LSC immunophenotype and expression of various LSC markers in m-LSCs. Supplementary Fig. 6: Molecular properties and targeting of m-LSCs in vitro and in vivo. Supplementary Fig. 7: M5 but not M4 patients showing significantly higher refractory rate to VEN/AZA therapy.
Supplementary Table S5 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
Authors: Subbiah Vivek , Sahai Vaibhav , Maglic Dejan , Bruderek Kamil , Touré B. Barry , Zhao Songping , Valverde Roberto , O'Hearn Patrick J. , Moustakas Demetri T. , Schönherr Heike , Gerami-Moayed Nastaran , Taylor Alexander M. , Hudson Brandi M. , Houde Damian J. , Pal Debjani , Foster Lindsey , Gunaydin Hakan , Ayaz Pelin , Sharon Dina A. , Goyal Lipika , Schram Alison M. , Kamath Suneel , Sherwin Cori Ann , Schmidt-Kittler Oleg , Jen Kai Yu , Ricard Fabien , Wolf Beni B. , Shaw David E. , Bergstrom Donald A. , Watters James , Casaletto Jessica B.
Published: September 2023

Fold change in potency against FGFR2 acquired resistance mutations
Supplementary Table S3 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
Authors: Subbiah Vivek , Sahai Vaibhav , Maglic Dejan , Bruderek Kamil , Touré B. Barry , Zhao Songping , Valverde Roberto , O'Hearn Patrick J. , Moustakas Demetri T. , Schönherr Heike , Gerami-Moayed Nastaran , Taylor Alexander M. , Hudson Brandi M. , Houde Damian J. , Pal Debjani , Foster Lindsey , Gunaydin Hakan , Ayaz Pelin , Sharon Dina A. , Goyal Lipika , Schram Alison M. , Kamath Suneel , Sherwin Cori Ann , Schmidt-Kittler Oleg , Jen Kai Yu , Ricard Fabien , Wolf Beni B. , Shaw David E. , Bergstrom Donald A. , Watters James , Casaletto Jessica B.
Published: September 2023

Antiproliferative effect of RLY-4008 and pan-FGFRi in human tumor cell lines
Supplementary Excel S3 from Dynamic Glycoprotein Hyposialylation Promotes Chemotherapy Evasion and Metastatic Seeding of Quiescent Circulating Tumor Cell Clusters in Breast Cancer
Authors: Dashzeveg Nurmaa K. , Jia Yuzhi , Zhang Youbin , Gerratana Lorenzo , Patel Priyam , Shajahan Asif , Dandar Tsogbadrakh , Ramos Erika K. , Almubarak Hannah F. , Adorno-Cruz Valery , Taftaf Rokana , Schuster Emma J. , Scholten David , Sokolowski Michael T. , Reduzzi Carolina , El-Shennawy Lamiaa , Hoffmann Andrew D. , Manai Maroua , Zhang Qiang , D'Amico Paolo , Azadi Parastoo , Colley Karen J. , Platanias Leonidas C. , Shah Ami N. , Gradishar William J. , Cristofanilli Massimo , Muller William A. , Cobb Brian A. , Liu Huiping
Published: September 2023

Supplementary Excel S3 shows the results of RNA sequencing.
Supplementary Figure S1 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
Authors: Subbiah Vivek , Sahai Vaibhav , Maglic Dejan , Bruderek Kamil , Touré B. Barry , Zhao Songping , Valverde Roberto , O'Hearn Patrick J. , Moustakas Demetri T. , Schönherr Heike , Gerami-Moayed Nastaran , Taylor Alexander M. , Hudson Brandi M. , Houde Damian J. , Pal Debjani , Foster Lindsey , Gunaydin Hakan , Ayaz Pelin , Sharon Dina A. , Goyal Lipika , Schram Alison M. , Kamath Suneel , Sherwin Cori Ann , Schmidt-Kittler Oleg , Jen Kai Yu , Ricard Fabien , Wolf Beni B. , Shaw David E. , Bergstrom Donald A. , Watters James , Casaletto Jessica B.
Published: September 2023

Supplementary Figure 1. RLY-4008 is an irreversible inhibitor of FGFR2.
Supplementary Appendix S1 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
Authors: Subbiah Vivek , Sahai Vaibhav , Maglic Dejan , Bruderek Kamil , Touré B. Barry , Zhao Songping , Valverde Roberto , O'Hearn Patrick J. , Moustakas Demetri T. , Schönherr Heike , Gerami-Moayed Nastaran , Taylor Alexander M. , Hudson Brandi M. , Houde Damian J. , Pal Debjani , Foster Lindsey , Gunaydin Hakan , Ayaz Pelin , Sharon Dina A. , Goyal Lipika , Schram Alison M. , Kamath Suneel , Sherwin Cori Ann , Schmidt-Kittler Oleg , Jen Kai Yu , Ricard Fabien , Wolf Beni B. , Shaw David E. , Bergstrom Donald A. , Watters James , Casaletto Jessica B.
Published: September 2023

ReFocus entry criteria
Supplementary Table 3 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
Authors: Facchinetti Francesco , Hollebecque Antoine , Braye Floriane , Vasseur Damien , Pradat Yoann , Bahleda Rastislav , Pobel Cédric , Bigot Ludovic , Déas Olivier , Florez Arango Juan David , Guaitoli Giorgia , Mizuta Hayato , Combarel David , Tselikas Lambros , Michiels Stefan , Nikolaev Sergey I. , Scoazec Jean-Yves , Ponce-Aix Santiago , Besse Benjamin , Olaussen Ken A. , Loriot Yohann , Friboulet Luc
Published: September 2023

IC50 values of Ba/F3 cells harboring FGFR3:TACC3 mutants exposed to eight selective FGFR inhibitors.
Supplementary Table 2 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
Authors: Facchinetti Francesco , Hollebecque Antoine , Braye Floriane , Vasseur Damien , Pradat Yoann , Bahleda Rastislav , Pobel Cédric , Bigot Ludovic , Déas Olivier , Florez Arango Juan David , Guaitoli Giorgia , Mizuta Hayato , Combarel David , Tselikas Lambros , Michiels Stefan , Nikolaev Sergey I. , Scoazec Jean-Yves , Ponce-Aix Santiago , Besse Benjamin , Olaussen Ken A. , Loriot Yohann , Friboulet Luc
Published: September 2023

Systemic treatment received by patients prior to selective FGFR inhibitors, according to the detection of FGFR kinase domain mutations and/or PI3K/mTOR pathway alterations.
Supplementary Figure 3 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
Authors: Facchinetti Francesco , Hollebecque Antoine , Braye Floriane , Vasseur Damien , Pradat Yoann , Bahleda Rastislav , Pobel Cédric , Bigot Ludovic , Déas Olivier , Florez Arango Juan David , Guaitoli Giorgia , Mizuta Hayato , Combarel David , Tselikas Lambros , Michiels Stefan , Nikolaev Sergey I. , Scoazec Jean-Yves , Ponce-Aix Santiago , Besse Benjamin , Olaussen Ken A. , Loriot Yohann , Friboulet Luc
Published: September 2023

Acquisition of mutations in PI3K/TSC1 pathway at progression to FGFR inhibitors.
Supplementary Figure 1 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
Authors: Facchinetti Francesco , Hollebecque Antoine , Braye Floriane , Vasseur Damien , Pradat Yoann , Bahleda Rastislav , Pobel Cédric , Bigot Ludovic , Déas Olivier , Florez Arango Juan David , Guaitoli Giorgia , Mizuta Hayato , Combarel David , Tselikas Lambros , Michiels Stefan , Nikolaev Sergey I. , Scoazec Jean-Yves , Ponce-Aix Santiago , Besse Benjamin , Olaussen Ken A. , Loriot Yohann , Friboulet Luc
Published: September 2023

RNAseq analysis from tissue biopsies of 39 advanced urothelial cancers.
Data from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
Authors: Subbiah Vivek , Sahai Vaibhav , Maglic Dejan , Bruderek Kamil , Touré B. Barry , Zhao Songping , Valverde Roberto , O'Hearn Patrick J. , Moustakas Demetri T. , Schönherr Heike , Gerami-Moayed Nastaran , Taylor Alexander M. , Hudson Brandi M. , Houde Damian J. , Pal Debjani , Foster Lindsey , Gunaydin Hakan , Ayaz Pelin , Sharon Dina A. , Goyal Lipika , Schram Alison M. , Kamath Suneel , Sherwin Cori Ann , Schmidt-Kittler Oleg , Jen Kai Yu , Ricard Fabien , Wolf Beni B. , Shaw David E. , Bergstrom Donald A. , Watters James , Casaletto Jessica B.
Published: September 2023

Abstract
Oncogenic activation of fibroblast growth factor receptor 2 (FGFR2) drives multiple cancers and represents a broad therapeutic opportunity, yet selective targeting of FGFR2 has not been achieved. Although the clinical efficacy of pan-FGFR inhibitors (pan-FGFRi) validates FGFR2 driver status in FGFR2 fusion–positive intrahepatic cholangiocarcinoma, their benefit is limited by incomplete target coverage due to FGFR1- and FGFR4-mediated toxicities (hyperphosphatemia and diarrhea, respectively) and the emergence of FGFR2 resistance mutations. RLY-4008 is a highly selective, irreversible FGFR2 inhibitor designed to overcome these limitations. In vitro, RLY-4008 demonstrates >250- and >5,000-fold selectivity over FGFR1 and FGFR4, respectively, and targets primary alterations and resistance mutations. In vivo, RLY-4008 induces regression in multiple xenograft models—including models with FGFR2 resistance mutations that drive clinical progression on current pan-FGFRi—while sparing FGFR1 and FGFR4. In early clinical testing, RLY-4008 induced responses without clinically significant off-isoform FGFR toxicities, confirming the broad therapeutic potential of selective FGFR2 targeting.
Significance:
Patients with FGFR2-driven cancers derive limited benefit from pan-FGFRi due to multiple FGFR1–4-mediated toxicities and acquired FGFR2 resistance mutations. RLY-4008 is a highly selective FGFR2 inhibitor that targets primary alterations and resistance mutations and induces tumor regression while sparing other FGFRs, suggesting it may have broad therapeutic potential.

See related commentary by Tripathi et al., p. 1964.

This article is featured in Selected Articles from This Issue, p. 1949
Data from Sex-Biased T-cell Exhaustion Drives Differential Immune Responses in Glioblastoma
Authors: Lee Juyeun , Nicosia Michael , Hong Ellen S. , Silver Daniel J. , Li Cathy , Bayik Defne , Watson Dionysios C. , Lauko Adam , Kay Kristen E. , Wang Sabrina Z. , Johnson Sadie , McGraw Mary , Grabowski Matthew M. , Kish Danielle D. , Desai Amar B. , Goodman Wendy A. , Cameron Scott J. , Okada Hideho , Valujskikh Anna , Fairchild Robert L. , Ahluwalia Manmeet S. , Lathia Justin D.
Published: September 2023

Abstract
Sex differences in glioblastoma (GBM) incidence and outcome are well recognized, and emerging evidence suggests that these extend to genetic/epigenetic and cellular differences, including immune responses. However, the mechanisms driving immunologic sex differences are not fully understood. Here, we demonstrate that T cells play a critical role in driving GBM sex differences. Male mice exhibited accelerated tumor growth, with decreased frequency and increased exhaustion of CD8+ T cells in the tumor. Furthermore, a higher frequency of progenitor exhausted T cells was found in males, with improved responsiveness to anti–PD-1 treatment. Moreover, increased T-cell exhaustion was observed in male GBM patients. Bone marrow chimera and adoptive transfer models indicated that T cell–mediated tumor control was predominantly regulated in a cell-intrinsic manner, partially mediated by the X chromosome inactivation escape gene Kdm6a. These findings demonstrate that sex-biased predetermined behavior of T cells is critical for inducing sex differences in GBM progression and immunotherapy response.
Significance:
Immunotherapies in patients with GBM have been unsuccessful due to a variety of factors, including the highly immunosuppressive tumor microenvironment in GBM. This study demonstrates that sex-biased T-cell behaviors are predominantly intrinsically regulated, further suggesting sex-specific approaches can be leveraged to potentially improve the therapeutic efficacy of immunotherapy in GBM.

See related commentary by Alspach, p. 1966.

This article is featured in Selected Articles from This Issue, p. 1949
Data from A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy
Authors: Pei Shanshan , Shelton Ian T. , Gillen Austin E. , Stevens Brett M. , Gasparetto Maura , Wang Yanan , Liu Lina , Liu Jun , Brunetti Tonya M. , Engel Krysta , Staggs Sarah , Showers William , Sheth Anagha Inguva , Amaya Maria L. , Minhajuddin Mohammad , Winters Amanda , Patel Sweta B. , Tolison Hunter , Krug Anna E. , Young Tracy N. , Schowinsky Jeffrey , McMahon Christine M. , Smith Clayton A. , Pollyea Daniel A. , Jordan Craig T.
Published: September 2023

Abstract
The BCL2 inhibitor venetoclax has recently emerged as an important component of acute myeloid leukemia (AML) therapy. Notably, use of this agent has revealed a previously unrecognized form of pathogenesis characterized by monocytic disease progression. We demonstrate that this form of disease arises from a fundamentally different type of leukemia stem cell (LSC), which we designate as monocytic LSC (m-LSC), that is developmentally and clinically distinct from the more well-described primitive LSC (p-LSC). The m-LSC is distinguished by a unique immunophenotype (CD34−, CD4+, CD11b−, CD14−, CD36−), unique transcriptional state, reliance on purine metabolism, and selective sensitivity to cladribine. Critically, in some instances, m-LSC and p-LSC subtypes can co-reside in the same patient with AML and simultaneously contribute to overall tumor biology. Thus, our findings demonstrate that LSC heterogeneity has direct clinical significance and highlight the need to distinguish and target m-LSCs as a means to improve clinical outcomes with venetoclax-based regimens.
Significance:
These studies identify and characterize a new type of human acute myeloid LSC that is responsible for monocytic disease progression in patients with AML treated with venetoclax-based regimens. Our studies describe the phenotype, molecular properties, and drug sensitivities of this unique LSC subclass.

This article is featured in Selected Articles from This Issue, p. 1949
FIGURE 5 from PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction In Vitro and In Vivo
Authors: Fröhlich Lisa Marie , Niessner Heike , Sauer Birgit , Kämereit Sofie , Chatziioannou Eftychia , Riel Simon , Sinnberg Tobias , Schittek Birgit
Published: September 2023

MAPKi induce HRD phenotype and thereby act synthetic lethal in combination with PARPi. A, Immunofluorescence of A375 S cells that were treated with 5 μmol/L talazoparib (Tala.), 5 μmol/L vemurafenib (Vem.), or a combination of both inhibitors (Combi.) for 24 hours, or remained untreated (Ctr.). Green: pH2AX, blue: DAPI. 40X magnification was used. Number of pH2AX foci per cell was counted and one-way ANOVA was performed to analyze the differences between the groups. B, Comet Assay was performed using A375 S cells that were treated with either 15 μmol/L talazoparib (Tala.), 5 μmol/L vemurafenib (Vem.), a combination of both drugs (Combi.) for 24 hours or remained untreated (Ctr.). Green: DNA. 10X magnification was used. C, RNA expression of MAPKi sensitive (S), vemurafenib resistant (R), or vemurafenib and trametinib double-resistant (RR) A375 cells after the treatment with 5 μmol/L vemurafenib (Vem.), 10 nmol/L trametinib (Trame.), or 5 μmol/L LY3009120 (LY.) for 24 hours. The relative gene expression of the treated cells compared with the control group is shown.
FIGURE 4 from PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction In Vitro and In Vivo
Authors: Fröhlich Lisa Marie , Niessner Heike , Sauer Birgit , Kämereit Sofie , Chatziioannou Eftychia , Riel Simon , Sinnberg Tobias , Schittek Birgit
Published: September 2023

Synthetic lethality elicits synergism in the combination of MAPKi with PARPi. MUH cell viability assay of A375 R or A375 RR cells treated with different concentrations of talazoparib (Tala.), vemurafenib (Vem.; A), trametinib (Trame.; B), LY3009120 (LY.; C) or a combination of these drugs (Combi.) for 72 hours. D, MUH cell viability assay of A375 and SKMel28 S cells treated with different concentrations of olaparib (Ola.), talazoparib (Tala.), vemurafenib (Vem.) or a combination of these drugs (Combi.) for 72 hours. E, SKMel28 S spheroids were treated with 5 μmol/L talazoparib (Tala.), 2.5 μmol/L vemurafenib (Vem.), a combination of both inhibitors (Combi.) in collagen for 6 days or remained untreated. The total size of the spheroids was quantified and multiple t test was performed to compare the groups at day 6. Representative pictures of the spheroids are shown. F, Colony formation of SKMel28 S and A375 S was analyzed after the treatment with 2 μmol/L talazoparib (Tala.), 2 μmol/L vemurafenib (Vem.), a combination of both drugs (Combi.) for 7 days or untreated cells (Ctr.). The number of colonies per well was counted. One-way ANOVA was used to compare each group with each other. G, NSG mice were treated with control vehicle (Ctr.), 1 mg/kg/day talazoparib (Tala.), 25 mg/kg/day (Vem.), or a combination of both inhibitors (Combi). The xenograft tumor volume in percent compared with treatment start over time is shown. Multiple t test was used to compare the Ctr. group with the Combi. group. H, The final tumor volume of the individual mice of G is depicted. Multiple t test was used to compare the different groups with each other.
Table S3 from Single-cell Profiling Uncovers a Muc4-Expressing Metaplastic Gastric Cell Type Sustained by Helicobacter pylori-driven Inflammation
Authors: O'Brien Valerie P. , Kang Yuqi , Shenoy Meera K. , Finak Greg , Young William C. , Dubrulle Julien , Koch Lisa , Rodriguez Martinez Armando E. , Williams Jeffery , Donato Elizabeth , Batra Surinder K. , Yeung Cecilia C.S. , Grady William M. , Koch Meghan A. , Gottardo Raphael , Salama Nina R.
Published: September 2023

Genes driving the clustering of cells in UMAP #2. Up to the top 70 genes with the highest fold change and Padjusted < 0.05 are given for each cluster.
FIGURE 2 from PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction In Vitro and In Vivo
Authors: Fröhlich Lisa Marie , Niessner Heike , Sauer Birgit , Kämereit Sofie , Chatziioannou Eftychia , Riel Simon , Sinnberg Tobias , Schittek Birgit
Published: September 2023

PARPi treatment induces p53-associated proapoptotic genes and cell death in BRAFi resistant melanoma cells. A, Migration and Invasion assay using A375 R cells that were treated with 5 μmol/L talazoparib (Tala.) for 24 hours or remained untreated (Ctr.) is shown. The relative number of migrated (left) or invaded (right) cells is shown. Unpaired t test was performed to compare the Ctr. with Tala. group. B, Cell-cycle analysis was performed in A375 R, 451Lu R, and Mel1617 R cells after treatment with 2 μmol/L talazoparib (Tala.) for 24, 72, or 120 hours. Untreated cells (Ctr.) served as a control. C, Incucyte Caspase-3/7 Dye for apoptosis was used to trace cell death activation after treatment of 5 μmol/L talazoparib (Tala.) for up to 48 hours compared with untreated cells (Ctr.). The percentage of green fluorescence positive cells is shown. Unpaired t test was performed to compare the Ctr. with Tala. group. D, RT2 Profiler PCR Array Human p53 Signaling Pathway was performed in A375 R cells that were treated with 5 μmol/L talazoparib for 24 hours or remained untreated. log2 fold changed in the expression of the corresponding genes between the talazoparib treated group and the control group as well as the log10P values of the respective gene expression changes are shown in the volcano plot. Technical triplicates were performed. E, Immunoblot analysis of A375 R, 451Lu R, and Mel1617 R cells treated with 5 μmol/L talazoparib (+) for 24 hours or untreated (−). Relative protein expression is shown. F, Relative gene expression of CDKN1A after 5 μmol/L talazoparib (Tala.) treatment for 24 hours or untreated A375 R, 451Lu R, and Mel1617 R cells. Unpaired t test was performed to compare the Ctr. with Tala. group.
Table S2 from Single-cell Profiling Uncovers a Muc4-Expressing Metaplastic Gastric Cell Type Sustained by Helicobacter pylori-driven Inflammation
Authors: O'Brien Valerie P. , Kang Yuqi , Shenoy Meera K. , Finak Greg , Young William C. , Dubrulle Julien , Koch Lisa , Rodriguez Martinez Armando E. , Williams Jeffery , Donato Elizabeth , Batra Surinder K. , Yeung Cecilia C.S. , Grady William M. , Koch Meghan A. , Gottardo Raphael , Salama Nina R.
Published: September 2023

Genes driving the clustering of cells in UMAP #1; genes with power ≥ 0.4 are given.